サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584125

エストロゲン受容体陽性乳がん治療市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測

Estrogen Receptor Positive Breast Cancer Treatment Market, By Drug Class, By Therapy Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
エストロゲン受容体陽性乳がん治療市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

エストロゲン受容体陽性乳がん治療市場規模は2023年に198億1,032万米ドルとなり、2024年から2032年にかけてCAGR 7.90％で拡大

エストロゲン受容体陽性乳がん治療市場-市場力学

乳がん検診・診断に対する意識の高まりがエストロゲン受容体陽性乳がん治療市場の成長を牽引

乳がん検診と診断に対する意識の高まりは、エストロゲン受容体陽性乳がん治療市場の成長を大きく促進します。これは、早期発見により、限局した段階で診断された場合の生存率が99%まで上昇することを報告する全米乳がん財団によって証明されています。乳がん啓発月間のような取り組みやSusan G. Komenのような組織によるキャンペーンは、定期的な検診の重要性に関する一般市民の知識を高め、過去10年間でマンモグラフィ受診率が30％増加することにつながった。さらに、米国がん協会は、乳がんの約70％がER陽性であることを強調し、このサブタイプに特化した標的治療の重要性を強調しています。ヘルスケアプロバイダーが高度なスクリーニング技術や遺伝子検査を日常診療に取り入れるようになるにつれて、効果的な治療法に対する需要が高まり、腫瘍学の重要な分野であるこの分野の市場成長がさらに促進されると予想されます。

エストロゲン受容体陽性乳がん治療市場-主要洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約7.90%のCAGRで毎年成長すると推定されます。

薬剤クラス別では、選択的エストロゲン受容体モジュレーター（SERM）が2023年に最大の市場シェアを示すと予測されます。

治療タイプ別では、ホルモン療法が2023年の主要タイプです。

投与経路別では、2023年には経口剤が主要タイプとなっています。

地域別では、北米が2023年の主要収益源でした。

エストロゲン受容体陽性乳がん治療市場-セグメンテーション分析：

エストロゲン受容体陽性乳がん治療の世界市場は、薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、地域別に区分されます。

薬剤クラス別に4つに分類される：選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、サイクリン依存性キナーゼ（CDK）阻害剤、PI3K阻害剤です。選択的エストロゲン受容体モジュレーター（SERM）は、ER+乳がんに対する有効性が確立されているため、最上位にランクされています。アロマターゼ阻害薬がこれに続き、閉経後の女性に広く使用されています。サイクリン依存性キナーゼ（CDK）阻害剤が脚光を浴びつつある一方、PI3K阻害剤はやや低い順位にあります。

市場は治療法の種類によって4つのカテゴリーに分けられる：ホルモン療法、化学療法、標的療法、免疫療法です。ホルモン療法は、ER+乳がんに対する有効性から最も優先順位が高いです。標的療法は、治療の正確性を提供し、その後に続く。化学療法は第3位で、しばしば併用され、免疫療法は新興の治療法ではあるが、現在のところこの分野での適用度は低いです。

エストロゲン受容体陽性乳がん治療市場-地理的洞察

北米はエストロゲン受容体陽性乳がん治療市場をリードしており、これは先進的なヘルスケアシステムと国民の高い認識レベルに牽引されています。米国は、National Breast and Cervical Cancer Early Detection Program（全米乳がん・子宮頸がん早期発見プログラム）のようなイニシアチブを実施しており、開始以来400万件以上の検診を実施し、早期発見率を大幅に向上させています。欧州もこれに追随しており、英国のような国々ではしっかりとした乳がん検診プログラムが確立され、約85％の女性が早期診断を受けています。アジア太平洋地域では、特に日本やインドのような国々で乳がん罹患率が上昇しているため、政府は啓発キャンペーンや検診イニシアチブの強化を促しています。例えば、インドのNational Health Missionは、検診率を高めるために地域ベースのプログラムを開始しました。ラテンアメリカでは、乳がんに対する認識と治療オプションへのアクセスが徐々に向上しており、中東・アフリカでは、乳がんの負担増に対処するためにヘルスケアインフラの改善と患者教育に注力しています。

エストロゲン受容体陽性乳がん治療市場-競合情勢：

エストロゲン受容体陽性乳がん治療市場の競合情勢は、北米の主要企業が特徴的であり、アストラゼネカやファイザーのような企業が革新的な治療で主導権を握っています。2023年には、アストラゼネカがHER2陽性乳がんをターゲットとする新薬Enhertuを発売し、腫瘍学ポートフォリオをさらに拡大しました。欧州では、ロシュが重要な競争相手であり続け、個別化医療のアプローチを進めるために様々な研究機関と積極的に共同研究を行っています。例えば、ロシュとケンブリッジ大学との共同研究は、治療効果の予測バイオマーカーの開発を目指しています。アジア太平洋地域では、ノバルティスや武田薬品などの企業が躍進しており、ノバルティスは新興市場でのがん領域のパイプライン拡充に投資しています。ファイザーによるアレイ・バイオファーマの買収など、最近の合併は乳がん治療開発における能力を強化しています。さらに、ER+乳がんに対する併用療法に焦点を当てた提携が増加しており、イノベーションと戦略的提携を通じて患者のアンメットニーズへの対応を目指す各社が、強固な競合環境を示唆しています。

目次

第1章 エストロゲン受容体陽性乳がん治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 エストロゲン受容体陽性乳がん治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 エストロゲン受容体陽性乳がん治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 エストロゲン受容体陽性乳がん治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 エストロゲン受容体陽性乳がん治療市場情勢

  • エストロゲン受容体陽性乳がん治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 エストロゲン受容体陽性乳がん治療市場-薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • 選択的エストロゲン受容体モジュレーター（SERM）
    • アロマターゼ阻害剤
    • サイクリン依存性キナーゼ（CDK）阻害剤
    • PI3K阻害剤

第8章 エストロゲン受容体陽性乳がん治療市場- 治療タイプ別

  • 概要
    • 治療タイプ別セグメントシェア分析
    • ホルモン療法
    • 化学療法
    • 標的療法
    • 免疫療法

第9章 エストロゲン受容体陽性乳がん治療市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 経口
    • 静脈注射

第10章 エストロゲン受容体陽性乳がん治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • 専門クリニック
    • 外来手術センター

第11章 エストロゲン受容体陽性乳がん治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- エストロゲン受容体陽性乳がん治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company, Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Johnson &Johnson
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4108

REPORT HIGHLIGHT

Estrogen Receptor Positive Breast Cancer Treatment Market size was valued at USD 19,810.32 Million in 2023, expanding at a CAGR of 7.90% from 2024 to 2032.

The Estrogen Receptor Positive Breast Cancer Treatment Market focuses on therapies targeting estrogen receptor-positive (ER+) breast cancer, which constitutes about 70% of all breast cancer cases and significantly influences treatment decisions. Increasing awareness about breast cancer screening and diagnosis is boosting market growth, as evidenced by the American Cancer Society reporting over 300,000 new cases of breast cancer in the U.S. annually. The rise in targeted therapies and the approval of novel drugs like CDK4/6 inhibitors are transforming treatment paradigms. However, challenges such as high treatment costs and the potential for drug resistance can hinder market expansion. Additionally, the lack of access to advanced therapies in low-income regions represents a restraint. Opportunities lie in the development of combination therapies and personalized medicine approaches, particularly in emerging markets where healthcare systems are evolving to incorporate advanced cancer treatment options, potentially improving patient outcomes and driving market dynamics in the coming years.

Estrogen Receptor Positive Breast Cancer Treatment Market- Market Dynamics

Growing Awareness of Breast Cancer Screening and Diagnosis Drives Growth in the Estrogen Receptor Positive Breast Cancer Treatment Market

Growing awareness of breast cancer screening and diagnosis significantly drives growth in the Estrogen Receptor Positive Breast Cancer Treatment Market, as evidenced by the National Breast Cancer Foundation reporting that early detection can increase survival rates to 99% when diagnosed at localized stages. Initiatives like Breast Cancer Awareness Month and campaigns from organizations such as Susan G. Komen have heightened public knowledge about the importance of regular screenings, leading to a 30% increase in mammogram rates in the past decade. Moreover, the American Cancer Society emphasizes that approximately 70% of breast cancers are ER-positive, highlighting the importance of targeted treatments that cater specifically to this subtype. As healthcare providers increasingly integrate advanced screening techniques and genetic testing into routine care, the demand for effective therapies is expected to rise, further propelling market growth in this vital area of oncology.

Estrogen Receptor Positive Breast Cancer Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Selective Estrogen Receptor Modulators (SERMs) were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Hormonal therapy was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Estrogen Receptor Positive Breast Cancer Treatment Market- Segmentation Analysis:

The Global Estrogen Receptor Positive Breast Cancer Treatment Market is segmented on the basis of Drug Class, Therapy Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Drug Class: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Cyclin-Dependent Kinase (CDK) Inhibitors, and PI3K Inhibitors. Selective Estrogen Receptor Modulators (SERMs) rank highest due to their established efficacy in treating ER+ breast cancer. Aromatase inhibitors follow, widely used in postmenopausal women. Cyclin-dependent kinase (CDK) inhibitors are gaining prominence, while PI3K inhibitors rank slightly lower in application.

The market is divided into four categories based on Therapy Type: Hormonal Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy. Hormonal therapy holds the highest priority due to its effectiveness for ER+ breast cancer. Targeted therapy follows closely, offering precision in treatment. Chemotherapy ranks third, often used in combination, while immunotherapy, although emerging, currently has a lower application in this context.

Estrogen Receptor Positive Breast Cancer Treatment Market- Geographical Insights

North America leads the Estrogen Receptor Positive Breast Cancer Treatment Market, driven by advanced healthcare systems and high awareness levels among the population. The U.S. has implemented initiatives like the National Breast and Cervical Cancer Early Detection Program, which provided over 4 million screenings since its inception, significantly improving early detection rates. Europe follows closely, where countries like the UK have established robust breast cancer screening programs, leading to approximately 85% of women being diagnosed at an early stage. In the Asia-Pacific region, rising breast cancer incidence, especially in countries like Japan and India, is prompting governments to enhance awareness campaigns and screening initiatives. For instance, India's National Health Mission has launched community-based programs to increase screening rates. Latin America is experiencing a gradual increase in awareness and access to treatment options, while the Middle East & Africa are focusing on improving healthcare infrastructure and patient education to tackle the rising burden of breast cancer, reflecting a growing commitment to address this significant health issue.

Estrogen Receptor Positive Breast Cancer Treatment Market- Competitive Landscape:

The competitive landscape of the Estrogen Receptor Positive Breast Cancer Treatment Market is characterized by key players in North America, where companies like AstraZeneca and Pfizer lead the charge with innovative therapies. In 2023, AstraZeneca launched its new drug, Enhertu, which targets HER2-positive breast cancer, further expanding its oncology portfolio. In Europe, Roche remains a significant competitor, actively collaborating with various research institutions to advance personalized medicine approaches. For example, Roche's collaboration with the University of Cambridge aims to develop predictive biomarkers for treatment efficacy. In the Asia-Pacific region, companies like Novartis and Takeda are making strides, with Novartis investing in expanding its oncology pipeline in emerging markets. Recent mergers, such as Pfizer's acquisition of Array BioPharma, enhance its capabilities in breast cancer treatment development. Additionally, increasing partnerships focused on combining therapies for ER+ breast cancer signal a robust competitive environment, with companies aiming to address the unmet needs of patients through innovation and strategic collaborations.

Recent Developments:

In October 2024, The FDA approved a new three-drug combination for ER-positive, HER2-negative breast cancer, significantly improving progression-free survival. The treatment includes inavolisib, fulvestrant, and palbociclib, effectively targeting PIK3CA mutations in patients resistant to standard therapies.

In June 2024, AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) have been approved in the EU for advanced ER-positive breast cancer patients with specific biomarker alterations. The combination significantly reduces disease progression risk by 50% compared to Faslodex alone, based on CAPItello-291 trial results.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Others

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Selective Estrogen Receptor Modulators (SERMs)
  • Aromatase Inhibitors
  • Cyclin-Dependent Kinase (CDK) Inhibitors
  • PI3K Inhibitors

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

GLOBAL ESTROGEN RECEPTOR POSITIVE BREAST CANCER TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Estrogen Receptor Positive Breast Cancer Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Drug Class
    • 2.1.2. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Therapy Type
    • 2.1.3. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Route of Administration
    • 2.1.4. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by End-User
    • 2.1.5. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Country
    • 2.1.6. Estrogen Receptor Positive Breast Cancer Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Estrogen Receptor Positive Breast Cancer Treatment Key Market Trends

  • 3.1. Estrogen Receptor Positive Breast Cancer Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Estrogen Receptor Positive Breast Cancer Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Opportunities
  • 3.4. Estrogen Receptor Positive Breast Cancer Treatment Market Future Trends

4. Estrogen Receptor Positive Breast Cancer Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Estrogen Receptor Positive Breast Cancer Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Estrogen Receptor Positive Breast Cancer Treatment Market Landscape

  • 6.1. Estrogen Receptor Positive Breast Cancer Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Estrogen Receptor Positive Breast Cancer Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Selective Estrogen Receptor Modulators (SERMs)
    • 7.1.3. Aromatase Inhibitors
    • 7.1.4. Cyclin-Dependent Kinase (CDK) Inhibitors
    • 7.1.5. PI3K Inhibitors

8. Estrogen Receptor Positive Breast Cancer Treatment Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 8.1.2. Hormonal Therapy
    • 8.1.3. Chemotherapy
    • 8.1.4. Targeted Therapy
    • 8.1.5. Immunotherapy

9. Estrogen Receptor Positive Breast Cancer Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Estrogen Receptor Positive Breast Cancer Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Ambulatory Surgical Centers

11. Estrogen Receptor Positive Breast Cancer Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Estrogen Receptor Positive Breast Cancer Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Estrogen Receptor Positive Breast Cancer Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Boehringer Ingelheim GmbH
    • 12.2.6. Bristol-Myers Squibb Company
    • 12.2.7. Daiichi Sankyo Company, Limited
    • 12.2.8. Eli Lilly and Company
    • 12.2.9. F. Hoffmann-La Roche AG
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Takeda Pharmaceutical Company Limited
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us